SCHEMBL21401736

SCHEMBL21401736

C=C(/C=C\N=C/C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14307306 0.74
SCHEMBL23189485 0.74
SCHEMBL21037686 0.72
SCHEMBL20962995 0.72
SCHEMBL22701432 0.70
SCHEMBL19370585 0.69
SCHEMBL18574529 0.69
SCHEMBL23891446 0.68
SCHEMBL25148173 0.68
SCHEMBL24885641 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148104-A1 COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN BioAge Labs, Inc. (US) 2024-07-11 WO disclosed
EP-3860714-B1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS INC (US) 2023-09-06 EP disclosed
US-20230134821-A1 MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-05-04 US disclosed
US-11066447-B2 Aureobasidium derivatives and methods of synthesis AueroGen Biosciences, Inc. (US) 2021-07-20 US disclosed
US-20190292225-A1 AUREOBASIDIUM DERIVATIVES AND METHODS OF SYNTHESIS AUREOGEN BIOSCIENCES, INC. 2019-09-26 US disclosed